RMD Open (Oct 2024)

Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel

  • György Nagy,
  • David Szabo,
  • Alexandra Balogh,
  • Laszlo Gopcsa,
  • Laura Giba-Kiss,
  • Gergely Lakatos,
  • Melinda Paksi,
  • Marienn Reti,
  • Peter Takacs,
  • Pearl van Heteren,
  • Gregor Zadoyan,
  • Silke Holtkamp,
  • Toon Overstijns,
  • Stefan Miltenyi,
  • Peter Remenyi

DOI
https://doi.org/10.1136/rmdopen-2024-004727
Journal volume & issue
Vol. 10, no. 4

Abstract

Read online

We report the case of long-term persisting rheumatoid arthritis (RA), treated with CD20-CD19 CAR-T when it became associated with diffuse large B cell lymphoma (DLBCL), resulting in a sustained drug-free remission of the preceding RA, as well as of the subsequent DLBCL that formed the indication of the CAR-T therapy using zamtocabtagene autoleucel, with a 1-year follow-up. According to our best knowledge, this is the first published clinical case report of long-term persisting RA treated with CAR-T cell therapy.